ADMA Biologics faces an August 10, 2026 deadline for lead plaintiff applications in a securities class action lawsuit
Executive summary: Kahn Swick & Foti LLC informed investors that they have until August 10, 2026 to file lead plaintiff applications in a class action lawsuit alleging securities fraud against ADMA Biologics. The deadline underscores continuing legal risk for ADMA, with potential financial penalties, share‑price volatility, and heightened regulatory scrutiny of biotech disclosures.
Who is involved: ADMA Biologics, its shareholders, the law firm Kahn Swick & Foti (partner Charles C. Foti Jr., former Louisiana Attorney General), and the putative class of investors.
Likely next: Before the August 10 deadline, investors may submit lead plaintiff applications; the court will then select a lead plaintiff and proceed with litigation, potentially leading to discovery, settlement, or trial.
Kahn Swick & Foti, LLC, together with former Louisiana Attorney General Charles C. Foti Jr., notified ADMA Biologics investors that they must submit lead plaintiff applications by August 10, 2026 to participate in a class action alleging securities fraud. The notice follows a series of similar KSF‑issued deadlines for other companies, indicating a coordinated effort by the firm to pursue putative shareholder claims. While the announcement does not prejudge the outcome, it highlights ongoing legal exposure that could affect ADMA’s finances and investor confidence.
Timeline
- — ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline (PR Newswire)
Analysis — what this means
Likely next events
- August 10, 2026: deadline for lead plaintiff applications in ADMA class action
- August 10, 2026: same deadline for Via Transportation and Erasca class actions
- Week of August 15, 2026: anticipated court hearing on lead plaintiff motions
Sectors affected
- Biotechnology
- Biologics
- Pharmaceuticals
Regulatory implications
- SEC may increase scrutiny of ADMA’s disclosures under Securities Exchange Act §10(b)
- If violations are proven, ADMA could face civil penalties and disgorgement under federal securities laws
- The repeated KSF notices suggest a pattern of litigation risk for biotech firms with volatile stock moves
Historical parallels
- July 14, 2026: ADMA Biologics class action filed after stock fell ~29% following Culper Research channel‑stuffing allegations
- July 13, 2026: ADMA sued for alleged violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934
Key entities
Sources
Related cases
- Pomerantz Law Firm files class action against ADMA Biologics, with investor deadline of August 10, 2026, amid repeated securities fraud alerts
- ADMA Biologics faces renewed securities litigation pressure as DJS Law Group reactivates investor outreach for August 2026 class action
- ADMA Biologics faces a looming August 10 deadline for investors to assume lead plaintiff role in a securities fraud class action, highlighting ongoing litigation risk for the biotech firm
- Rosen Law Firm reminds ADMA Biologics investors of the August 10 deadline to serve as lead plaintiff in a securities fraud class action
- ADMA Biologics faces an August 10 deadline for lead plaintiff applications in a securities fraud class action
- ADMA Biologics faces a securities class action alleging violations of federal anti‑fraud statutes, raising legal and investor confidence risks